| ￥3500 | |
| Z04180-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 51.8 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 62-65 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized CD27 Ligand/CD70 Trimer, His, Human, His Tag at 2 μg/ml (100 μL/well) on the plate. Dose response curve for Human CD27, hFc Tag with the EC50 of 11.8 ng/ml determined by ELISA. »
The purity of CD27 Ligand/CD70 Trimer, His, Human is greater than 95% as determined by SEC-HPLC. »
CD27 Ligand/CD70 Trimer, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | CD70, also named CD27 ligand (CD27L), is a type II transmembrane glycoprotein belonging to the TNF superfamily (TNFSF) and has been designated TNFSF7. CD70 is a cytokine that binds to CD27. Plays a role in T-cell activation. Induces the proliferation of costimulated T-cells and enhances the generation of cytolytic T-cells. |
| Synonyms | CD70 molecule; CD70; TNFSF7; CD27 Ligand; CD27-L; CD27LG; Ki-24 antigen; TNFSF7G |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
